When University of Texas at Arlington researcher Paul J. Fadel and his colleagues launched a study on vascular health in people with chronic kidney disease, they expected to better understand a long-standing belief. For years, scientists have pointed to a blood marker called ADMA—asymmetric dimethylarginine—as a warning sign for vascular problems.
This article was originally published on MedicalXpress.com